Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Revumenib with Cytarabine, Daunorubicin and Midostaurin for the Treatment of Patients with NPM1 and FLT3 Mutated Acute Myeloid Leukemia

Trial Status: active

This phase I trial tests safety, side effects and best new dose of revumenib in combination with cytarabine, daunorubicin and midosataurin for the treatment of patients with NPMI and FLT3 mutated acute myeloid leukemia (AML). Revumenib is in a class of medications called menin inhibitors. It works by blocking the action of an abnormal menin-MLL complex that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them. Chemotherapy drugs, such as cytarabine, daunorubicin and midosataurin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving revumenib with cytarabine, daunorubicin and midosataurin may be safe and tolerable in treating patients with NPMI and FLT3 mutated AML.